(Print or Type Responses)

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average b	urden					
hours per response	0.5					

longer subject to Section 16. Form 4 or Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* GOWER JAMES M					2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X_Director 10% Owner					
(Eirst) (Middle) RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 03/30/2009						X							
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If A	4. If Amendment, Date Original Filed(Month/Day/Year)						_X_ I	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
SOUTH (Ci		(State)	(Zip)														
		(55)		1	_					ative Securities					1.		
(Instr. 3) Date		2. Transaction Date (Month/Day/Y	ear) Exe	ecuti	on Date, if	Coc (Ins	Transaction de str. 8)	(A)	Securities Acqui or Disposed of str. 3, 4 and 5)	(D) Owned Followin Transaction(s)			C F	wnership orm:	7. Nature of Indirect Beneficial		
				(M	onth	/Day/Year)		Code V Amount (D) Price (Instr. 3 and 4)				o: (I	Indirect (	Ownership Instr. 4)			
Reminder:	Report on a s	separate line for each	n class of securities b	II - Der	ivati	ive Securiti	ies A	Pe thi cu	ersons vis form arrently	who respond are not requi- valid OMB co d of, or Benefic ertible securiti	red to respontrol num	oond unles ber.			n SEC 1	474 (9-02)	
Security	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	Code		5. Number Derivative Securities Acquired ( or Dispose (D) (Instr. 3, 4 and 5)	(A) ed of	Expiration Date (Month/Day/Year)		of Underly Securities	Securities Instr. 3 and 4)		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownershi Form of Derivative Security: Direct (D) or Indirec	(Instr. 4)		
				Code	v	(A)	(D)	Date Exercisa	ible	Expiration Date	Title	Amount or Number of Shares		(instr. 4)	(Ilistr. 4)		
Stock Option (Right to Buy)	\$ 6.49	03/30/2009		A		190,000		04/30/2	2009 <mark>(1</mark>	03/30/2019	Common Stock	190,000	\$ 0	190,000	D		

# **Reporting Owners**

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
GOWER JAMES M RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	X		CEO & Board Chairman				

# **Signatures**

/s/ Dolly Vance (Attorney-in-Fact)	03/31/2009
**Signature of Reporting Person	Date

# **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C.
- (1) The shares vest monthly over one (1) year from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.